Literature DB >> 8348694

Loss of asymmetric distribution of sarcolemmal phosphatidylethanolamine during simulated ischemia in the isolated neonatal rat cardiomyocyte.

R J Musters1, E Otten, E Biegelmann, J Bijvelt, J J Keijzer, J A Post, J A Op den Kamp, A J Verkleij.   

Abstract

In the present study we have investigated the reorganization of the sarcolemmal phospholipids during the first 60 minutes of simulated ischemia ("ischemia") as induced by anoxia, volume restriction, and nutrient deprivation. Experiments were carried out on [3H]acetate-labeled neonatal rat cardiomyocytes and isolated (nonradiolabeled) sarcolemmal membranes obtained from the same culture system. After 60 minutes of "ischemia," cellular high-energy phosphate (ATP) levels had decreased to approximately 40% of the control values, but no significant phospholipid hydrolysis was detected. Labeling experiments using the nonpermeant (primary amine-containing phospholipid) probe trinitrobenzenesulfonic acid and nonlytic treatment with (different) exogenous phospholipases A2 were both indicative of a shifted transbilayer distribution of the hexagonalII phase-preferring and fusion-promoting sarcolemmal phosphatidylethanolamine in favor of the outer membrane leaflet. This specific change in sarcolemmal phospholipid asymmetry preceded the loss of integrity of the sarcolemma, monitored by the release of lactate dehydrogenase as well as by scanning electron microscopy. It is proposed that, in addition to the previously reported lateral phospholipid reorganization, uncontrolled transbilayer movement of the non-bilayer-preferring phosphatidylethanolamine from the inner to the outer leaflet of the sarcolemma is an additional factor in destabilizing the lipid bilayer, eventually leading to the irreversible membrane damage seen after a prolonged period of ischemia.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8348694     DOI: 10.1161/01.res.73.3.514

Source DB:  PubMed          Journal:  Circ Res        ISSN: 0009-7330            Impact factor:   17.367


  8 in total

Review 1.  Sarcolemmal dependence of cardiac protection and stress-resistance: roles in aged or diseased hearts.

Authors:  Louise E See Hoe; Lauren T May; John P Headrick; Jason N Peart
Journal:  Br J Pharmacol       Date:  2016-09-09       Impact factor: 8.739

2.  Reversible and irreversible damage in reoxygenated 'ischemic' ventricular myocytes in culture.

Authors:  A Pinson; R Tirosh
Journal:  Mol Cell Biochem       Date:  1996 Jul-Aug       Impact factor: 3.396

3.  The feasibility of imaging myocardial ischemic/reperfusion injury using (99m)Tc-labeled duramycin in a porcine model.

Authors:  Lei Wang; Feng Wang; Wei Fang; Steven E Johnson; Said Audi; Michael Zimmer; Thomas A Holly; Daniel C Lee; Bao Zhu; Haibo Zhu; Ming Zhao
Journal:  Nucl Med Biol       Date:  2014-09-23       Impact factor: 2.408

4.  Potent cardioprotection from ischemia-reperfusion injury by a two-domain fusion protein comprising annexin V and Kunitz protease inhibitor.

Authors:  C-H Yeh; T-P Chen; Y-C Wang; S-W Fang; T-C Wun
Journal:  J Thromb Haemost       Date:  2013-08       Impact factor: 5.824

5.  Modulation of the phase heterogeneity of aminoglycerophospholipid mixtures by sphingomyelin and monovalent cations: maintenance of the lamellar arrangement in the biological membranes.

Authors:  Cedric Tessier; Peter Quinn; Kamen Koumanov; Germain Trugnan; Dominique Rainteau; Claude Wolf
Journal:  Eur Biophys J       Date:  2004-03-03       Impact factor: 1.733

6.  Mechanisms underlying taurine-mediated alterations in membrane function.

Authors:  S W Schaffer; J Azuma; J D Madura
Journal:  Amino Acids       Date:  1995-09       Impact factor: 3.520

Review 7.  Phospholipid Asymmetry in Biological Membranes: Is the Role of Phosphatidylethanolamine Underappreciated?

Authors:  Abhijit Chakrabarti
Journal:  J Membr Biol       Date:  2021-01-19       Impact factor: 1.843

8.  Left-shifted nav channels in injured bilayer: primary targets for neuroprotective nav antagonists?

Authors:  Catherine E Morris; Pierre-Alexandre Boucher; Béla Joós
Journal:  Front Pharmacol       Date:  2012-02-23       Impact factor: 5.810

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.